New Issue: Credit Suisse prices $1.96 million 8.5% autocallable reverse convertibles on Alexion

By Susanna Moon

Chicago, Dec. 29 – Credit Suisse AG, London Branch priced $1.96 million of 8.5% autocallable reverse convertible securities due Dec. 29, 2015 linked to Alexion Pharmaceuticals, Inc. shares, according to a 424B2 filing with the Securities and Exchange Commission.

Interest will be payable monthly.

The notes will be called at par if the stock closes at or above the initial share price on either observation date.

If the notes are not called, the payout at maturity will be par unless Alexion stock closes at or below the knock-in level, 70% of the initial share price, during the life of the notes and finishes below the initial share price, in which case investors will be fully exposed to any losses.

Credit Suisse Securities (USA) LLC is the agent.

Issuer:	Credit Suisse AG, London Branch
Issue:	Autocallable reverse convertible securities
Underlying stock:	Alexion Pharmaceuticals, Inc. (Symbol: ALXN)
Amount:	$1,957,000
Maturity:	Dec. 29, 2015
Coupon:	8.5%, payable monthly
Price:	Par
Payout at maturity:	Par unless Alexion stock closes at or below knock-in price during life of notes and finishes below initial share price, in which case 5.590652 shares
Call:	At par if stock closes at or above initial share price on June 24, 2015 or Sept. 24, 2015
Initial share price:	$178.87
Knock-in price:	$125.209, 70% of initial share price
Pricing date:	Dec. 23
Settlement date:	Dec. 29
Agent:	Credit Suisse Securities (USA) LLC
Fees:	2.1%
Cusip:	22547QYU4

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.